 LAVAL, Quebec--BUSINESS WIRE--BELLUS Health Inc. Nasdaq:BLU; TSX:BLU BELLUS Health or the Company, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Healths President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton Co. Healthcare Investor Conference. Presentation Detail 